Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

(13,026)NISUSDLOSS PER ORDINARY SHARE - BASIC AND DILUTED(0.13)

(0.08)

(0.31)

(0.21)

(0.02)

(0.06) BioLineRx Ltd.CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS(UNAUDITED)Convenience translationinto USDNine months ended September 30,Nine months endedSeptember 30,201220132013NIS in thousandsIn thousandsCASH FLOWS - OPERATING ACTIVITIESComprehensive loss for the period

(51,842)

(46,074)

(13,026)Adjustments required to reflect net cash used in
operating activities (see appendix below)

(724)

(9,837)

(2,782)Net cash used in operating activities

(52,566)

(55,911)

(15,808)CASH FLOWS - INVESTING ACTIVITIESInvestments in short-term deposits

(48,992)

(104,127)

(29,439)Maturities of short-term deposits

64,801

85,377

24,138Maturities of restricted deposits

-

1,550

438Purchase of property and equipment

(545)

(196)

(55)Purchase of intangible assets

(21)

(96)

(27)Net cash provided by (used in) investing activities

15,243

(17,492)

(4,945)CASH FLOWS - FINANCING ACTIVITIESRepayments of bank loan

(224)

(127)

(36)Issuance of share capital and warrants, net of issuance expenses

52,453

50,140

14,176Proceeds from exercise of employee stock options

*

*

*Net cash provided by financing activities

52,229

50,013

14,140INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS14,906

(23,390)

(6,613)CASH AND CASH EQUIVALENTS – BEGINNINGOF PERIOD33,061

68,339

19,321EXCHANGE DIFFERENCES ON CASH AND CASH
EQUIVALENTS4,931

(1,988)

(562)CASH AND CASH EQUIVALENTS - END OF PERIOD52,898

42,961

12,146* Less than 1,000 BioLine
'/>"/>

SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
9. BioLineRx to Present at 15th International Celiac Disease Symposium
10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
11. BioLineRx Appoints B. J. Bormann to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  Shares of Aerie ... of their value yesterday following the results of the ... therapy, Rhopressa.  Despite the trial failing to meet its ... positive results may come from future studies. ... company overview, current pipeline, financial review, analyst summary, valuation, ...
(Date:4/30/2015)... Abaxis, Inc. (NasdaqGS: ABAX ), a ... reported financial results for the fourth quarter and fiscal ... and fiscal 2015 overview: , Revenues from continuing ... 33% over last year,s comparable quarter, and $202.6 million ... EPS of $0.50 for the fourth quarter, up 194% ...
(Date:4/30/2015)...  Accuray Incorporated (Nasdaq: ARAY ) announced ... MIM Software Inc. to further develop adaptive therapy ... product portfolios. The new software solution will ... Accuray,s second collaboration with MIM; the previous partnership ... treatment plan review capability, PlanTouch™. "Accuray ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
... 23, 2012  (OTC: IFIX) Internal Fixation Systems today announced ... to market subtalar implants. These implants are used to ... both trauma conditions and arthritis.  IFS CEO, Stephen Dresnick, ... to fill out our portfolio, and gives us another ...
... Dana Taschner from the Los Angeles office of ... California,s best lawyers in the annual Southern California Super Lawyers ... Taschner has earned the Super Lawyers distinction. He holds ... The Best Lawyers in America , one of the leading guides ...
Cached Medicine Technology:Internal Fixation Systems Announces 510(k) Approval Granted by FDA for Subtalar Implants 2The Lanier Law Firm's Dana Taschner Recognized Among Southern California's Top Lawyers 2
(Date:5/2/2015)... Ticket Down has secured additional inventories of ... awaited event today, Saturday, May 2nd at the MGM Grand ... be able to secure tickets for both the actual fight ... fans have wanted for more than five years was finally ... will step inside the ring to fight Manny “Pac-Man” Pacquiao ...
(Date:5/2/2015)... May 02, 2015 We are pleased ... Delray Recovery Center as one of the Top Workplaces ... in the addiction treatment field for their ethics and ... innovate and to continue their educational efforts. The Delray ... environment, never forgetting their purpose – to help individuals ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare announces ... new healthcare insurance to individuals and small businesses on ... is the nation’s first health insurance system built from ... Health Insurance was ZoomCare’s first such filing including rates ... review and regulation by the Oregon Insurance Division. Once ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
(Date:5/1/2015)... Hope For The Warriors® thanks All American ... Warriors® and military families. All American Ford presented two ... Warriors®, a national nonprofit dedicated to restoring a sense ... for our service members and our military families. , ... and matched small autograph fee from fans and presented ...
Breaking Medicine News(10 mins):Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2
... Wood was Mayo pioneer in aerospace medicineROCHESTER, Minn., March ... investigator credited with inventing the high-altitude pressure suit worn ... Minn. He was 97. "As both a physician and ... leadership to Mayo Clinic and scientific advancements to the ...
... for as Little as 35 CentsSAN CLEMENTE, Calif., March 23 ... forward to every morning. But at about three dollars ... nearly $1100 a year! In these tough economic times, ... reducing their latte consumption, but their calcium intake as well. ...
... La., March 23 Brain Gym(R) provides a simple ... and adults every day; difficulties with reading, writing, math, ... movement. Brain Gym(R) is based on the use ... process for Brain Balance, which can break through cognitive ...
... a debilitating fall. But a University of Illinois at Chicago ... by practicing the Chinese martial art of tai chi. , ... has studied and used tai chi as a way to ... she and a colleague have seen similar results in a ...
... WASHINGTON, March 23 Jesse Buchanan of Minden, NV, ... Tuesday, March 31, 2009 to meet with congressional leaders ... and more research toward a cure for epilepsy.Buchanan, 14, ... country participating in Kids Speak Up! , a ...
... Webcast to Discuss Key Trends Changing the Face of Global Pharma Marketing ... ... Manhattan Research, a global healthcare and pharmaceutical market research company, ... in emerging markets amidst the need for global best practices. The presentation ...
Cached Medicine News:Health News:Inventor of G-Suit Dies 2Health News:Inventor of G-Suit Dies 3Health News:Inventor of G-Suit Dies 4Health News:Boost Your Calcium Consumption - Have a Latte! 2Health News:Boost Your Calcium Consumption - Have a Latte! 3Health News:Learning Empowered by Movement; Brain Gym Exercises Wake Up Brain and Body 2Health News:Stroke survivors improve balance with tai chi 2Health News:Nevada Youth Shares Epilepsy Message On Capitol Hill 2Health News:Manhattan Research: Physician New Media Adoption in Emerging Pharma Markets - Webcast April 3 2Health News:Manhattan Research: Physician New Media Adoption in Emerging Pharma Markets - Webcast April 3 3
... VelaSmooth is the first and ... with the revolutionary elos combined ... Frequency and Infrared Light ... suction to reduce the appearance ...
... result of DEKA's new technology ... different methods capable of restoring,a ... treatment is designed to dramatically ... the combined action of a ...
... SilkPeel Dermalinfusion is the ... of deliver a topical dermaceutical ... effectively treats all skin types ... of dermatological conditions including hyperpigmentation, ...
... Novalis offers the Clareon to practices that ... treatment speed and efficacy. The versatility of ... a wide range of treatments that would ... never need to worry about obsolescence because ...
Medicine Products: